6 recruiting, 3 active not recruiting, 3 completed, 2 terminated. 9 Phase 2, 8 Phase 1, 2 Not applicable, 1 Phase 3.
Follow Mesotheliomas Pleural: new trials by email Literature Review of Mesotheliomas Pleural trials Research Report on Mesotheliomas Pleural
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma Partial Pleurectomy - Mesothelioma, Mesothelioma; Lung | Not applicable | Recruiting | University of Chicago | 30 | 2025-12-02 | 2026-02-17 |
| A Study of Sacituzumab Govitecan in People With Mesothelioma Sacituzumab govitecan-hziy - Mesothelioma, Mesotheliomas Pleural | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 33 | 2024-06-21 | 2026-05-28 |
| Ga-68 FAPI PET Before Immunotherapy Ga-68 FAPI PET/CT - Mesotheliomas Pleural | Not applicable | Unknown | Ankara University | 30 | 2024-04-30 | 2024-06-11 |
| Immune Microenvironment and Gene Expression Profiling in Mesothelioma Translation analysis - Mesothelioma, Mesotheliomas Pleural | Completed | Istituto Oncologico Veneto IRCCS | 125 | 2023-11-02 | 2026-09-25 | |
| Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM) Pembrolizumab, Indocyanine Green (ICG) Image-Guided Surgery, Cisplatin - Mesotheliomas Pleural | Phase 1 | Recruiting | Abramson Cancer Center at Penn Medicine | 20 | 2023-01-10 | 2025-12-04 |
| Oral AMXT 1501 Dicaprate in Combination With IV DFMO AMXT1501, DFMO - Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Aminex Therapeutics, Inc. | 15 | 2022-11-29 | 2024-12-24 |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer TC-510, Fludarabine, Cyclophosphamide - Mesothelioma, Mesotheliomas Pleural | Phase 1 / Phase 2 | Terminated | TCR2 Therapeutics | 14 | 2022-06-21 | 2026-07-13 |
| The IMmunotherapy Pleural 5-ALA PDT intrapleural photodynamic therapy with videothoracoscopy, Nivolumab Injection - Mesotheliomas Pleural, Malignant Pleural Mesothelioma | Phase 2 | Recruiting | University Hospital, Lille | 20 | 2022-05-09 | 2025-09-25 |
| Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma RSO-021 - Malignant Pleural Effusion, Malignant Pleural Mesothelioma | Phase 1 / Phase 2 | Completed | RS Oncology LLC | 50 | 2022-03-31 | 2026-07-24 |
| Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) Atezolizumab 1200 mg in 20 ML Injection, Placebo - Mesotheliomas Pleural | Phase 3 | Recruiting | Gruppo Oncologico Italiano di Ricerca Clinica | 162 | 2021-12-14 | 2025-03-13 |
| dENdritic Cell Therapy Combined With SURgEry in Mesothelioma Mesopher - Mesotheliomas Pleural | Phase 1 | Recruiting | Erasmus Medical Center | 16 | 2021-11-02 | 2026-09-29 |
| Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients Pembrolizumab, Lenvatinib - Mesotheliomas Pleural | Phase 2 | Active not recruiting | The Netherlands Cancer Institute | 58 | 2021-03-01 | 2024-11-05 |
| Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma UV1 vaccine + leukine, ipilimumab, nivolumab - Cancer, Cancer, Lung | Phase 2 | Active not recruiting | Åslaug Helland | 118 | 2020-05-04 | 2024-02-29 |
| A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma No intervention - Mesothelioma, Mesothelioma Malignant | Withdrawn | ProgenaBiome | 2020-03-02 | 2025-06-05 | ||
| Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer gavo-cel, fludarabine, cyclophosphamide - Mesothelioma, Mesothelioma, Malignant | Phase 1 / Phase 2 | Active not recruiting | TCR2 Therapeutics | 57 | 2019-04-15 | 2025-08-27 |
| A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib - Colorectal Cancer Not MSI-H or MMR-deficient, GIST | Phase 1 / Phase 2 | Unknown | Institut Bergonié | 747 | 2018-05-04 | 2023-03-03 |
| CAR T Cells in Mesothelin Expressing Cancers huCART-meso cells - Lung Adenocarcinoma, Ovarian Cancer | Phase 1 | Completed | University of Pennsylvania | 65 | 2017-04-06 | 2025-04-29 |
Mesothelioma, Malignant (17) · Mesothelioma (9) · Carcinoma, Non-Small-Cell Lung (4) · Ovarian Neoplasms (4) · Cholangiocarcinoma (2) · Colorectal Neoplasms (2) · Neoplasms (2) · Stomach Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Adenocarcinoma of Lung (1) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1)
Adenoma (17) · Lung Diseases (17) · Neoplasms by Histologic Type (17) · Neoplasms by Site (17) · Neoplasms, Glandular and Epithelial (17) · Neoplasms, Mesothelial (17) · Pleural Neoplasms (17) · Respiratory Tract Diseases (17) · Respiratory Tract Neoplasms (17) · Thoracic Neoplasms (17) · Lung Neoplasms (16) · Neoplasms (15) · Mesothelioma (8) · Adenocarcinoma (5) · Carcinoma (5)
Nivolumab (3) · Cyclophosphamide (2) · Ipilimumab (2) · fludarabine (2) · pembrolizumab (2) · Cisplatin (1) · Clinical Trials, Phase II as Topic (1) · Indocyanine Green (1) · Injections (1) · Pemetrexed (1) · Surgery, Computer-Assisted (1) · Thiostrepton (1) · Thoracic Surgery, Video-Assisted (1) · UV1 vaccine (1) · atezolizumab (1)
TCR2 Therapeutics (2) · Abramson Cancer Center at Penn Medicine (1) · Aminex Therapeutics, Inc. (1) · Ankara University (1) · Erasmus Medical Center (1) · Gruppo Oncologico Italiano di Ricerca Clinica (1) · Institut Bergonié (1) · Istituto Oncologico Veneto IRCCS (1) · Memorial Sloan Kettering Cancer Center (1) · ProgenaBiome (1) · RS Oncology LLC (1) · The Netherlands Cancer Institute (1) · University Hospital, Lille (1) · University of Chicago (1) · University of Pennsylvania (1)
United States (8) · Australia (2) · France (2) · Italy (2) · Netherlands (2) · Canada (1) · Denmark (1) · Norway (1) · Spain (1) · Sweden (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Arnaud Scherpereel, MD,PhD (1) · Corey Langer, MD (1) · Darren Bryan, MD (1) · Giulia Pasello, MD (1) · James Spicer, MD (1) · Janos L Tanyi, MD, PhD (1) · Michael Armstrong, MD (1) · Michael Offin, MD (1) · S Burgers, PhD (1) · Sabine Hazan, MD (1) · Sue Lee, MD (1)
PMID 34059094, PMID 34965951, PMID 34998048, PMID 37501016, PMID 37844598, PMID 39133306, PMID 40204996, PMID 40579407, PMID 41308680, PMID 42322509, PMID 42448681
2016 (1), 2019 (1)